{"groups":[{"description":"2x150mg film-coated tablets","id":"FG000","title":"Cohort A Olaparib 300mg bd"},{"description":"either enzalutamide capsules (160 mg od) or abiraterone acetate tablets (1,000 mg od with 5 mg bid prednisone)","id":"FG001","title":"Cohort A Investigators Choice of NHA"},{"description":"2x150mg film-coated tablets","id":"FG002","title":"Cohort B Olaparib 300mg bd"},{"description":"either enzalutamide capsules (160 mg od) or abiraterone acetate tablets (1,000 mg od with 5 mg bid prednisone)","id":"FG003","title":"Cohort B Investigators Choice of NHA"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"49"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"19"},{"groupId":"FG003","numSubjects":"12"}],"type":"Ongoing study at data cut off"},{"reasons":[{"groupId":"FG000","numSubjects":"88"},{"groupId":"FG001","numSubjects":"54"},{"groupId":"FG002","numSubjects":"67"},{"groupId":"FG003","numSubjects":"28"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}],"type":"Screen failure"},{"reasons":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"6"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Study terminated by sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Investigator decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}],"type":"Disease progression"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"162"},{"groupId":"FG001","numSubjects":"83"},{"groupId":"FG002","numSubjects":"94"},{"groupId":"FG003","numSubjects":"48"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"162"},{"groupId":"FG001","numSubjects":"83"},{"groupId":"FG002","numSubjects":"94"},{"groupId":"FG003","numSubjects":"48"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Subjects were divided into two cohorts based on HRR gene mutation status. Subjects with mutations in either BRCA1, BRCA2, or ATM are in Cohort A whereas subjects with mutations among 12 other genes involved in the HRR pathway (BARD1, BRIP1, CDK12, CHEK1,CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, or RAD54L) are in Cohort B."}